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PERSPECTIVE OPEN
Excessive early-life dietary exposure: a potential source of
elevated brain iron and a risk factor for Parkinson’s disease
Dominic J Hare1,2,3, Bárbara Rita Cardoso2,4, Erika P Raven5,6, Kay L Double7,8, David I Finkelstein2, Ewa A Szymlek-Gay9 and
Beverley-Ann Biggs1,10
Iron accumulates gradually in the ageing brain. In Parkinson’s disease, iron deposition within the substantia nigra is further
increased, contributing to a heightened pro-oxidant environment in dopaminergic neurons. We hypothesise that individuals in
high-income countries, where cereals and infant formulae have historically been fortiﬁed with iron, experience increased early-life
iron exposure that predisposes them to age-related iron accumulation in the brain. Combined with genetic factors that limit iron
regulatory capacity and/or dopamine metabolism, this may increase the risk of Parkinson’s diseases. We propose to (a) validate a
retrospective biomarker of iron exposure in children; (b) translate this biomarker to adults; (c) integrate it with in vivo brain iron in
Parkinson’s disease; and (d) longitudinally examine the relationships between early-life iron exposure and metabolism, brain iron
deposition and Parkinson’s disease risk. This approach will provide empirical evidence to support therapeutically addressing brain
iron deposition in Parkinson’s diseases and produce a potential biomarker of Parkinson’s disease risk in preclinical individuals.
npj Parkinsons Disease  (2017) 3:1 ; doi:10.1038/s41531-016-0004-y
INTRODUCTION
In their most recent guidelines for iron supplementation of infants
and children, the World Health Organisation (WHO) states that a
research priority should be the collection of ‘additional data on the
safety of iron supplementation [including] effects in non-an[a]emic
or non-iron-deﬁcient children’.1 We acknowledge that iron
fortiﬁcation and supplementation programs have been a widely
successful practice for reducing the incidence of iron deﬁciency
anaemia (IDA), though we wish to highlight the importance of
determining the optimal level of iron exposure to ensure IDA is
avoided while also limiting potential negative health outcomes
later in life. Ten-year follow-up studies of infants exposed to ‘off-
the-shelf’ formula products with high (12.7mg/L) iron content have
suggested possible negative long-term developmental outcomes,
justifying the need for studies of excessive early-life exposure in
iron-replete populations with respect to adverse neurological
effects. In this Perspective, we discuss the potential impact of long-
standing iron fortiﬁcation policies during periods of early-life brain
development (which we consider as 0–24 months) on age-related
iron accumulation and Parkinson’s disease (PD) risk.
Dopamine and iron dyshomeostasis in Parkinson’s disease
Abnormally elevated iron within the midbrain beyond that of
normal ageing2 is a pathological feature of PD.3 We have suggested
that neurodegeneration observed in PD is initiated by aberrant
reactions between redox-active iron and dopamine due to defective
mechanisms regulating both chemicals. Cellular and animal studies
have shown that prior neuronal iron accumulation (likely supple-
mented by glia and a neuronal labile iron pool that increases with
age)4 overwhelms iron storage mechanisms, releasing it into the
cytoplasm, where it interacts freely with dopamine to form toxic
metabolites,5 and that iron levels within the vulnerable substantia
nigra pars compacta region are elevated in the human PD brain.6
Overexpression of the key parkinsonian protein α-synuclein
promotes neuronal iron accumulation,7 while iron itself can
promote aggregation of mutated forms of this protein.8 Wild-type
mice, aged normally after elevated iron exposure from 10 to
14 days (equivalent to our proposed critical window in humans of
6–24 months postpartum), that had elevated exposure comparable
to iron-fortiﬁed infant formula had elevated nigral iron,9 increased
oxidative stress markers and dopaminergic-speciﬁc neuron loss
when assessed at 8 months of age, and a parkinsonian phenotype
apparent from 5 months.10 The damage elicited by iron supple-
mentation could be, in part, rescued using the low-afﬁnity iron
chelator clioquinol. However, when iron loading was combined
with overexpression of the A53T mutated form of human α-
synuclein associated with producing permeable dopamine-
containing vesicles, the phenotype could not be recovered.10
Dyshomeostasis of iron and dopamine in PD is potentially
hazardous. Numerous genetic mutations impair the function of α-
synuclein, which is involved in vesicular packaging of dopamine.11
Permeabilised vesicles can leak dopamine into the cytosol,
creating a neurotoxic iron-dopamine redox couple arising from
concurrent genetic mishandling of normal iron storage and
regulation.12–14 The reaction between dopamine and iron
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produces several highly neurotoxic metabolites of the catechola-
mine, which can eventually overwhelm endogenous antioxidant
mechanisms that protect neurons against elevated oxidative load.
Early-life exposure to high levels of iron may predispose the brain
to increased deposition with age,15 which further stresses
impaired genetic regulation of this essential metal. Polymorphisms
have been identiﬁed in the transferrin gene,13,14 as well as
increased expression of Ndﬁp1, a protein regulating the iron
import protein divalent metal transporter-1, in the human
substantia nigra.16 Parkinson-speciﬁc iron and dopamine metabo-
lism deﬁcits suggest that postnatal iron overload is unlikely to
solely cause disease. Rather, a multi-hit hypothesis involving
neuronal iron accumulation and defective genetic regulation of
iron and dopamine metabolism may be more appropriate, the
effects of which are exacerbated by excessive iron intake during
critical windows of iron-dependent neurodevelopment. Addition-
ally, multiple non-genetic risk factors, including coffee, alcohol and
tobacco consumption, dietary habits, inﬂammatory disorders and
occupational exposure to heavy metals (such as manganese) and
pesticides, may have a compounding effect.17 For instance, iron
and paraquat (as well as rotenone and the parkinsonian mimetic
MPTP)18 exhibit a synergistic effect promoting neurotoxicity in
sporadic PD.19 As with all epidemiological studies, particularly
those investigating late-age-onset diseases like PD, discerning the
direct effects of a single factor like early-life iron overload is
extremely difﬁcult.
Parkinson’s mortality and historical iron fortiﬁcation policies in
high-income countries
We hypothesise that individuals exposed to high dietary iron
during critical periods of neural development are at risk of
excessive iron accumulation in the brain. For example, in high-
income countries where cereals and infant formulae have
historically been fortiﬁed with iron, infants may experience
increased early-life iron exposure that predisposes them to age-
related iron accumulation in susceptible neurons in the midbrain,
which rapidly amasses iron during early life.2 Combined with
genetic factors that limit iron-regulatory capacity and/or dopa-
mine metabolism, this may increase the risk of PD.20
Given the association between brain iron and PD, we sought
epidemiological evidence that high-income countries that were
early adopters of food fortiﬁcation and iron supplementation
programs for infants may now be experiencing increasing rates of
PD. Public health policies regarding dietary iron supplementation
can be traced back nearly a century. The US began fortifying ﬂour
with iron in the 1930s to reduce IDA in the general population. This
approach was reinforced by an American Medical Association policy
in 193621 that was adopted by most high-income countries during
World War 2 and beyond, including countries receiving humanitar-
ian aid from the US.22 Other than the US (wheat, maize and rice)
and UK (wheat), where fortiﬁcation remains mandatory, most other
high-income countries either continue (e.g. Australia) or recently
abandoned a voluntary fortiﬁcation program (e.g. Sweden).23
Formula fortiﬁcation to address IDA in infants was ﬁrst endorsed
by the American Academy of Paediatrics in 1969 and enacted into
law in the Infant Formula Act (1980), though iron-enriched
formulae were available from 1959.24 Current AAP recommenda-
tions suggest fortiﬁed formula with 12mg/L of iron, in addition to
complementary foods (including those manufactured from
enriched grains and foods containing haem iron) from 6 months
of age;25 most high-income countries follow this guideline to
some degree. The European Society for Paediatric Gastroenterol-
ogy, Hepatology, and Nutrition considers fortiﬁcation of formula
fed to infants from 6 months safe and appropriate; however, a
speciﬁc level has not been set due to a cited lack of evidence for
optimal iron levels to prevent IDA, and typical concentrations are
4–8 mg/L.26 When taken together, formula and iron-enriched
cereal products account for a substantial portion of an infant’s
dietary iron intake; in Australia this constitutes 71.7 % of the total
iron intake for 9-month-old infants27 and 87.8 % for 6–12-month-
old infants in the US.28
Age-adjusted mortality rates for PD (according to ICD9 and 10)
in selected high-income countries show an increase from 50 years
(the age from which PD incidence increases)17 post introduction
of fortiﬁcation policies (Fig. 1). This is highest in the US and UK,
where fortiﬁcation of grains remains mandatory. Intrapolation of
data from alternative sources29–31 of PD mortality in the US and
UK shows a comparatively static rate of mortality following the
introduction of food fortiﬁcation policies. Interestingly, Japan,
which has no current or previous policy of mandatory nor
voluntary iron fortiﬁcation of grains, rice or infant formulae,32 is
the primary exception as PD-associated mortality remains
relatively low and static from 1979 to 2013. Genetic diversity with
regard to known mutations impacting iron metabolism in PD may
compound this feature. Interestingly, neither the PLA2G6 variant
to PARK1433 nor the ATP13A2 variant to PARK934 that have known
association with iron metabolism and PD have been identiﬁed in
large Japanese cohorts. A curiosity is observed from the limited PD
WHO data for Norway, where PD mortality is relatively high (7.434
± 0.810 per 100,000; 1996–2013) although iron fortiﬁcation of
common food products has been outlawed since the release of
the ﬁrst ‘White Paper’ on nutrition in 1976.35 However, infants are
encouraged to be fed iron-fortiﬁed porridge since 1963,36 though
a signiﬁcant ‘lag time’ to demonstrate an effect on PD mortality
Fig. 1 Age-adjusted mortality rates for PD in males and females from
selected high-income countries. All data were obtained from the WHO
mortality database (http://www.who.int/healthinfo/mortality_data/en/)
and were age-adjusted to the year 2000 population for each
country. Increasing PD mortality is most marked in the UK and USA
approximately 50–65 years following initiation of mandatory iron
fortiﬁcation of grains and milled ﬂour (1980–1995). Japan, with no
policy on iron fortiﬁcation, shows relatively stable mortality rates. PD
as the cause of death was deﬁned according to the ICD10 code G20
or ICD9 code 332 (both PD). Figures from the UK for 1984–1992 were
corrected for dual listing of PD as a chronic condition and a cause of
death reported by the Ofﬁce of Population Censuses and Surveys to
the WHO, as suggested by Clarke.29 Although WHO mortality data
extend only to 1979, Clarke showed that age-adjusted PD mortality
in the UK was relatively static in the decades preceding 1980
(†; dashed blue line).29 Pre-1979 mortality data for the US (‡) was
obtained from Hinz et al.30 and Lilienﬁeld et al.31 Note that these
ﬁgures are estimates only and are not age-adjusted to the
population at 2000. Mortality was used in place of prevalence or
incidence rates to remove confounding effects of improving
diagnosis or increasing disease duration though medical interven-
tion, such as the introduction of L-DOPA treatment in the early 1980s
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has not yet elapsed. It is unclear if widespread fortiﬁed foods were
available before 1976, which may contribute to high mortality
rates. Norway does have disproportionately high rates of
hereditary haemochromatosis37 that can result in basal ganglia
iron deposition. There is conﬂicting evidence as to whether the
C282Y, S65C and H63D mutations to the HFE gene are associated
with PD;38 most recent statistically powered studies have
suggested they are not.39,40
The increase in PD mortality we observed in the US is supported
by recent data reported by Savica et al.,41 who showed an increase
in PD prevalence occurring between 1976 and 2005 in a US-based
cohort of 906 patients, particularly in males. The authors
postulated a possible association between increased prevalence
with declining smoking behaviour during this period, though
acknowledged lifestyle and environmental factors may have
contributed to this trend. It should be noted that sex-based
Fig. 2 Flowchart for testing the early-life iron exposure hypothesis of PD risk. Biomarker validation: Two preclinical studies will be used to
validate and apply a tooth-based biomarker of elevated dietary iron exposure during the 0–24-month period, using children’s deciduous teeth
and adult teeth collected after routine dental extraction. Integration with in vivo brain iron imaging: Using the validated tooth biomarker, teeth
collected from PD patients and age-matched controls will be analysed for temporal iron levels and source (via temporal analysis of barium
levels)43 during the 0–24-month proposed critical window and assessed against iron deposition levels within the basal ganglia, measured by
iron-speciﬁc MRI methods. Assessment of PD risk: A cohort of mid-to-old age subjects would be recruited to longitudinally assess for PD risk,
based on stratiﬁcation of (a) high dietary iron and presence of selected genetic risk factors (e.g. iron/dopamine metabolic regulators; the
established PD genetic risk score); (b) high dietary iron exposure and no identiﬁed genetic risk factors; (c) low or normal early-life iron exposure
with presence of known genetic risk factors; and (d) neither high iron nor identiﬁed genetic risk. Correlation analysis between each group with
brain iron deposition (measured by MRI and TCS) and other preclinical measures of PD risk (e.g. hand and olfactory function and longitudinal
multifactorial rating scales) will be performed. Followed longitudinally, evidence of increased PD risk in line with the preclinical diagnostic criteria
set can be used to consider candidates for treatment with iron-chelating agents such as deferiprone56 to reduce brain iron burden and limit
potential oxidative reactions in dopaminergic neurons mediated by iron prior to, or immediately following, onset of clinical symptoms
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differences in PD prevalence and mortality are controversial;17 it
has been suggested that oestrogens increase striatal dopamine
levels.42 While this likely prolongs disease duration in females, it is
independent of potential increased risk from high iron exposure
during early life.
The report by Savica et al., combined with our assessment of PD
mortality in high-income countries, supports the hypothesis that
early-life iron exposure may increase PD risk in susceptible
individuals. However, testing this hypothesis is a difﬁcult task.
Establishing a birth cohort to link early-life iron intake to age-related
neurodegeneration in PD is impractical as it would not provide
answers for 60–70 years. As prevalence of clinical PD dramatically
increases above 65 years of age and is predicted to grow across all
age groups in the future,17 the broader effects of the uptake of
longstanding early-life iron fortiﬁcation programs we observed from
the late 1970s onwards may not be fully felt until 2030.
Testing the link between early-life iron exposure and PD risk
Blood iron levels provide only a relatively short window of
exposure, and thus a retrospective biomarker of iron intake is
needed. Humans retain a lifelong record of early-life iron exposure
in teeth, which we propose as one of four consecutive
experiments to test our hypothesis and translate our ﬁndings
into a biomarker of PD risk (Fig. 2). Firstly, deciduous teeth must
be established as a validated biomarker of early-life iron exposure.
During odontogenesis, metals are retained in hydroxyapatite
deposited in enamel and dentine. Using chemical microimaging,
alignment of spatial metal distribution with developmental
growth lines, akin to rings in a tree trunk, can be used to quantify
temporal iron exposure at time scales equivalent to 1 week.15
Detailed dietary data, including iron intake, for accessible cohorts
of infants can be repurposed to measure postnatal iron intake as
the children reach the ages of 5–8 years when teeth are shed.
Temporal growth lines and tooth iron concentrations can be
correlated with recorded dietary iron intakes during the 6–24-
month period. Further, spatial barium levels have been validated
as a biomarker of dietary sources in early life, and correlation with
iron distribution can differentiate between intake sources (i.e.
exclusive breastfeeding vs. fortiﬁed formula and iron-enriched
complementary feeding).43
This biomarker could then be applied to adult teeth to
investigate associations between early-life iron intake and iron
deposition in the ageing brain. Adult maxillary and mandibular ﬁrst
molars commence calciﬁcation at birth,44 and are therefore a record
of iron exposure during the proposed critical window in early
childhood. We suggest that adult teeth can be used to assess early-
life iron intake and dietary source, and quantiﬁed using chemical
microimaging without the need for deciduous teeth or patient
recall. In this phase of testing our hypothesis, donated permanent
teeth from healthy adults, individuals with clinically diagnosed PD
and age-matched controls would be used to quantify early-life iron
exposure, potential dietary sources, and to examine relationships
with brain iron levels. Teeth are often extracted during routine
dental procedures in older individuals; PD patients lose an average
of 18 adult teeth, with age-matched controls losing 14, likely due to
poor oral hygiene.45 Even in middle age, in the US the mean
number of teeth lost or extracted during dentistry is approximately
seven;46 tooth fragments obtained from dental crown implantation
or partial extractions can also be used.
In vivo imaging assesses the degree of midbrain iron deposition
and could be combined with a tooth biomarker of iron intake to
investigate the aetiology of PD. Magnetic resonance imaging (MRI)
techniques, including transverse relaxation rate (R2 or R2*) and
quantitative susceptibility mapping, are highly sensitive to the
paramagnetic effects of iron on T2* relaxation, an effect ampliﬁed at
high magnetic ﬁeld strengths. Several MRI studies have observed
elevated iron in the PD substantia nigra;47–49 however, continued
iron accumulation (which itself may be a useful tool for measuring
PD progression) occurs over the disease duration.50, 51 Transcranial
ultrasonography (TCS) also visualises increased iron-associated
echogenicity within the substantia nigra in PD,52 is stable
throughout disease duration53 and is of particular importance in
detecting early biochemical and motor function changes.54
Finally, to test our proposed link between iron exposure during
infancy and preclinical PD risk, we would establish an ‘at risk’ study
cohort of mid to old-aged individuals. Combining in vivo imaging
and genotyping of PD risk factors with our proposed tooth
biomarker would provide an unbiased historical record of iron
intake during the critical developmental window that imaging alone
could not achieve. Here, we would perform chemical assessments of
donated teeth and in vivo brain iron imaging, in addition to
detecting mutations to iron and dopamine regulatory genes known
to be associated with PD pathology.12 It is also important to
consider possible confounding inﬂuences on circulating iron levels
during early life, such as hereditary haemochromatosis. These
groups could then be stratiﬁed by early-life iron exposure (i.e. ‘low’
and ‘high’ risk; measured via tooth analysis), genetic markers and
other prodromal features, such as constipation, anxiety, depression
and anosmia. Subjects could then be recruited for longitudinal
population-based modelling of early PD detection,55 including
testing of hand and olfactory function and longitudinal PD rating
scales. Periodic in vivo brain iron assessment would project the
trajectory of age-related iron deposition and correlate this with
established preclinical features of PD (Fig. 2).
CONCLUSIONS
A link between early-life dietary iron and PD would have major
implications for public health policy, potentially prompting a
review of iron fortiﬁcation policies in countries in which IDA is no
longer a public health threat. The preclinical period of PD is 8–17
years. PD patients have already experienced signiﬁcant neurode-
generation at the time of diagnosis; therefore, identifying at-risk
individuals or those with early-stage disease will increase
opportunities to directly target the molecular basis of PD,
mitigating or even preventing dopamine denervation prior to
the onset of debilitating clinical symptoms. Empirical support for
the use of the high-afﬁnity iron chelator deferiprone in the early
stages of clinical PD has been reported by Devos et al.,56 who used
R2* MRI to conﬁrm a reduction in brain iron and improvements in
the Uniﬁed PD Rating Scale. This is now in phase II trials
(ClinicalTrials.gov Identiﬁer: NCT02728843).
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